No industry attracts louder AI marketing than medicine, and no industry punishes it harder. A sales tool that oversells costs you a bad quarter. A clinical tool that oversells costs trust, and sometimes more. So any honest survey of AI in healthcare has to start by sorting the field into three piles: what is deployed and working, what is genuinely promising but early, and what is a press release wearing a lab coat.
The good news is the first pile is real now. Clinicians who spent evenings finishing notes are using ambient scribes in actual exam rooms. Researchers who used to spend weeks screening papers for a literature review are running that screening in hours. Health systems are automating the administrative plumbing (scheduling, intake, follow-up calls) that never needed a doctor in the first place.
This piece walks through each pile, with the specific tools doing the work. Everything linked here comes from our directory, where you can browse the full collection of 241 AI tools for healthcare and life sciences.
Clinical documentation: where AI in healthcare earns its keep
Start with the least glamorous problem in medicine: the note. Every visit generates documentation, and for years the standing joke was that physicians see patients all day and do their real job — typing — at night.
Ambient scribes attack this directly. Nabla listens to the clinical conversation and drafts the note, offering ambient capture, dictation and real-time intelligence aimed at documentation quality and coding accuracy. Its stated goal is not futuristic medicine. It is reducing administrative burden and clinician burnout, which tells you who is actually buying it and why.
Abridge works the same territory, and the deployment evidence is worth reading firsthand. The UVM Health Network case study reports a 53% improvement in clinician fulfillment after rolling out Abridge's ambient documentation. That number matters precisely because it measures the clinician's working life, not a model benchmark.
The honest caveats: an ambient scribe drafts, it does not sign. Every note still needs clinician review before it enters the record, and a scribe that mishears a dosage or a negation ("no chest pain" versus "chest pain") produces an error that looks polished. The tools are good enough to save real time; they are not good enough to skip the read-through, and no serious vendor claims otherwise.
Literature research: the other deployment that already works
The second solid pile belongs to researchers, who have their own version of the documentation problem: the literature grows faster than anyone can read it.
Elicit searches across more than 138 million academic papers, automates parts of systematic literature reviews, and extracts data from papers into structured tables. The detail that matters most for medical use is sentence-level citations: every claim points at the exact sentence in the source, so verification is a click rather than an act of faith.
Consensus takes a different cut at the same problem: it is a search engine over peer-reviewed literature, built to answer questions with what published studies actually found, with filtering and summarization on top. Use Elicit when you are extracting and screening at volume. Use Consensus when you want a fast, sourced read on what the literature says about a specific question.
Neither replaces the judgment calls in a real systematic review: inclusion criteria, quality assessment, weighing conflicting findings. They compress the mechanical middle, and you should still spot-check extracted data against the source papers, because extraction errors are quiet ones.
For the writing end of research, Trinka AI is a grammar and language checker built specifically for academic, technical, and medical writing, with paraphrasing, plagiarism checks, and publication-readiness tools. Narrower than a general-purpose assistant, which is the point.
If this is your daily work, two browse pages are worth bookmarking: AI tools for researchers and tools for summarizing documents.
Admin automation: unglamorous, and quietly the biggest surface
The safest place to deploy AI in a health system is everywhere a patient interaction does not require clinical judgment: scheduling, benefits questions, discharge follow-up, care-gap outreach. It is also where the volume lives.
Hippocratic AI builds generative agents for exactly this territory, covering use cases like care management, patient access, and readmission prevention for health systems, payors, and pharma companies. The design decision worth studying: its agents do not diagnose and do not prescribe. That constraint is not a limitation to apologize for. It is the reason the product is deployable at all, and the company reports over 180 million clinical interactions to date.
In healthcare AI, the tools that scale first are the ones that drew their own boundaries before a regulator had to.
On the payor side, Oscar's case study describes using AI to automate health insurance processes and reduce costs. Claims-adjacent paperwork is another place where the stakes are financial rather than clinical, and iteration is therefore cheap.
Life-sciences companies are running the same play internally. Moderna's deployment of ChatGPT Enterprise is an organization-wide productivity rollout, not a clinical one. And the Novo Nordisk case study reports cutting clinical documentation work in drug development from weeks to minutes. Regulatory paperwork, it turns out, is a document problem, and document problems are what current models are best at.
The caveat here is escalation. A patient-facing agent is only as safe as its handoff: the moment a benefits call turns into "and I've been having chest pain," the system needs a human path that has been tested, not just designed.
Drug discovery: real science, long fuse
Structure prediction is the clearest case of AI doing something in biology that simply was not possible before. AlphaFold 3 predicts protein structures and their interactions with other molecules, and ESMFold2 predicts high-resolution, all-atom 3D structures from amino acid sequences, with open access to its models.
As research tools, these are deployed and working: structural biologists use them the way everyone else uses search. As a drug pipeline, the fuse is long. A predicted structure is a hypothesis, not a molecule; wet-lab validation, synthesis, and clinical trials still stand between the model output and a patient, and none of those stages got shorter because the first one did. File this pile as: working today for researchers, promising but early as a way to change what reaches the clinic.
Diagnostics at scale: the honest "not yet"
Diagnostic AI is where the marketing is loudest and the deployment story is thinnest, and the gap is structural, not a matter of model quality. A diagnostic tool is a regulated medical device. It has to prove itself on the populations and equipment of each site that uses it, integrate into clinical workflow, and answer the liability question of what happens when it is wrong.
None of that is impossible. Narrow diagnostic aids exist inside health systems today. But "AI reads your scan" as a consumer-scale reality is a pile-two claim being sold with pile-one confidence. It is telling that the working deployments in this article cluster around documentation, research and administration: the places where a wrong output is caught by a human review step that was already in the workflow.
| Category | Representative tools | Where it stands in 2026 |
|---|---|---|
| Clinical documentation | Nabla, Abridge | Deployed and working. Notes still need clinician sign-off |
| Literature research | Elicit, Consensus, Trinka | Deployed and working. Judgment calls stay human |
| Admin and patient ops | Hippocratic AI, Oscar | Deployed at volume. Safety rests on escalation paths |
| Drug discovery | AlphaFold 3, ESMFold2 | Working for researchers. Years from changing the clinic |
| Diagnostics at scale | None | Narrow aids exist. Broad claims outrun deployment |
How to tell the marketing from the product
A few patterns separate healthcare AI you can buy from healthcare AI that is mostly a landing page.
- The product states what it does not do. Hippocratic AI leading with "does not diagnose or prescribe" is a credibility signal, not a weakness.
- The evidence names a deployment. A case study at a specific health system beats an accuracy percentage with no denominator, no population, and no author.
- The workflow includes the human. Ask any vendor to walk you through the moment a clinician reviews, corrects, and signs the output. If the demo skips that step, the product skips it too.
- Wellness is labeled as wellness. Headspace (guided meditation, sleep resources, an AI companion, plus human coaching and therapy) and Rosebud, an AI journaling app that reflects your entries back with prompts and pattern insights, are honest about their lane. The red flag is not wellness apps existing. It is wellness apps borrowing clinical language they have not earned.
For staying current without drowning in vendor announcements, NEJM AI Grand Rounds is a good habit: conversations with people working at the intersection of machine learning and clinical practice, at a skepticism level this field deserves.
Frequently asked questions
What is AI actually used for in healthcare today?
The deployments with real traction in 2026 are ambient clinical documentation (tools like Nabla and Abridge drafting visit notes), literature research (Elicit and Consensus for finding and screening papers), and administrative automation (agents like Hippocratic AI handling scheduling, intake, and follow-up). Diagnostic AI exists in narrow, regulated forms but is far less broadly deployed than marketing suggests.
What is an AI medical scribe and do the notes still need review?
An AI medical scribe listens to the clinician–patient conversation and drafts the clinical note automatically, often with coding suggestions. Yes: every draft needs clinician review and sign-off before it enters the record. The value is the time saved drafting, not the removal of the review step.
Can AI research tools be trusted for medical literature reviews?
Tools like Elicit and Consensus ground their outputs in published papers, and Elicit provides sentence-level citations so claims can be verified against the source. They reliably compress the searching and screening work, but inclusion decisions, quality assessment, and interpretation of conflicting evidence should remain with the researcher, and extracted data is worth spot-checking.
Will AI replace doctors?
Nothing in the current deployment picture points that way. The tools working today remove documentation, search, and administrative load around clinical work rather than performing it. And the most successful vendors explicitly design their products not to diagnose or prescribe. The near-term change is doctors with less paperwork, not fewer doctors.
How should a clinic evaluate a healthcare AI tool before buying?
Pilot in real conditions on your hardest workflows, require deployment evidence from comparable organizations rather than benchmark numbers, and get data-handling terms (retention, training use, business associate agreement) in writing before any patient data flows. Then compare alternatives: our directory lists 241 AI tools for healthcare and life sciences, tagged by what they do.
